Patents by Inventor Smita Raghava

Smita Raghava has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE FORMULATIONS OF A MULTIVALENT VHH BASED CYTOTOXIC T LYMPHOCYTE ASSOCIATED ANTIGEN 4 (CTLA4) BINDER BINDING TO HUMAN CTLA4 AND METHODS OF USE THEREOF
    Publication number: 20260115137
    Abstract: The present disclosure relates to stable formulations comprising amino acid sequences and polypeptides binding to cytotoxic T-lymphocyte associated antigen 4 (CTLA4). In another aspect, the present disclosure relates, in part, to formulations comprising improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISVs” or “ISVDs”, or “multivalent VHH single domain antibodies”) binding to CTLA4, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs. Also provided are methods of treating various cancers and chronic infections with the formulations of the disclosure.
    Type: Application
    Filed: February 22, 2023
    Publication date: April 30, 2026
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jainik P. Panchal, Mark A. McCoy, Smita Raghava, Geetha Thiagarajan, Venus Hashemi
  • FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
    Publication number: 20240052036
    Abstract: The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
    Type: Application
    Filed: October 12, 2023
    Publication date: February 15, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Preeti G. Desai, Shuai Shi, Valentyn Antochshuk, Rubi Burlage, Smita Raghava
  • Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
    Patent number: 11845798
    Abstract: The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: December 19, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Preeti G. Desai, Shuai Shi, Valentyn Antochshuk, Rubi Burlage, Smita Raghava
  • FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
    Publication number: 20200055938
    Abstract: The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
    Type: Application
    Filed: May 1, 2018
    Publication date: February 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Preeti G. Desai, Shuai Shi, Valentyn Antochshuk, Rubi Burlage, Smita Raghava